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Acute renal impairment is common in patients with chronic liver disease, occurring in approximately 19% of hospitalised patients
with cirrhosis. A variety of types of renal impairment are recognised. The most important of these is the hepatorenal syndrome,
a functional renal impairment due to circulatory and neurohormonal abnormalities that underpin cirrhosis. It is one of the most
severe complications of cirrhosis with survival often measured in weeks to months. A variety of treatment options exist with early
diagnosis and appropriate treatment providing the best hope for cure. This paper provides a comprehensive and up-to-date review
of hepatorenal syndrome and lays out the topic according to the following sections: pathophysiology, historical developments,
diagnostic criteria and limitations, epidemiology, precipitating factors, predictors, clinical and laboratory findings, prognosis,
treatment options, prophylaxis, and conclusion.
1. Introduction
Hepatorenal syndrome (HRS) is a unique form of functional
renal failure due to diminished renal blood flow,which occurs
typically in kidneys that are histologically normal. It is a
severe complication of advanced liver disease and character-
istically affects patientswith cirrhosis and ascites. Prognosis is
poor with survival commonly measured in weeks to months.
Due to the absence of recognised biomarkers, the diagnosis
of HRS relies on a combination of clinical and laboratory cri-
teria. Several treatment options exist, and early diagnosis and
treatment provide the best hope of survival. In this paper, a
comprehensive review of HRS is presented based on current
knowledge. The information is organised according to the
following sections: pathophysiology, historical developments,
diagnostic criteria and limitations, epidemiology, precipi-
tating factors, predictors, clinical and laboratory findings,
prognosis, treatment options, prophylaxis, and conclusion.
2. Pathophysiology
The peripheral arterial vasodilation theory is the most
widely accepted explanation for the pathophysiology of HRS
(Figure 1) [1], which proposes that splanchnic vasodilation
that occurs as a consequence of portal hypertension with
cirrhosis is the inciting factor for the development of HRS.
Splanchnic vasodilation is mediated principally by nitric
oxide but also to a lesser extent by other vasodilator sub-
stances such as carbon monoxide, glucagon, vasodilator pep-
tides, and others. Splanchnic vasodilation sequesters blood
in the splanchnic vascular bed leading to a reduced effective
arterial blood volume (“arterial underfilling”). In compen-
sated cirrhosis, cardiac contractility and cardiac output
increase to counterbalance the reduction in systemic vascular
resistance. This temporarily maintains the effective arterial
blood volume. However, as the splanchnic vasodilation pro-
gresses the effective arterial blood volumeultimately declines.
At a late stage, the cardiac output may also fall due to the
development of cirrhotic cardiomyopathy. As the effec-
tive arterial blood volume declines, compensatory neuro-
hormonal vasoconstrictor systems such as the renin-angi-
otensin-aldosterone system (RAAS), the sympathetic ner-
vous system (SNS), and arginine vasopressin are stimulated.
This causes sodium and water retention, leading in turn to
ascites and hyponatraemia, as well as vasoconstriction of the
renal, cerebral, and peripheral vascular beds. In the kidneys,
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Figure 1: A flow diagram outlines the main pathophysiologic mechanisms involved in the development of HRS (reproduced with permission
from “JohnWiley and Sons,”Garcia-Tsao et al. [1]). RAAS—renin angiotensin aldosterone system; SNS—sympathetic nervous system;ADH—
antidiuretic hormone; HRS—hepatorenal syndrome.
local renal vasodilators such as prostaglandins are initially
able to counterbalance the effects of the neurohormonal vaso-
constrictor systems. Ultimately, this proves inadequate, as
renal vasoconstrictor tone predominates. The end result of
this process is a severe decline in renal blood flow leading
to reduced glomerular filtration rate (GFR) and the develop-
ment of HRS.
3. Historical Developments
The concept of HRS has its origins in important incremental
discoveries that extend as far back as the 19th century.
Frerichs (1861) and Flint (1863) reported an association
between advanced liver disease and a type of renal impair-
ment that is characterised by oliguria, the absence of protein-
uria, and normal renal histology [2, 3]. By relating the renal
impairment to disturbances in the systemic circulation, the
authors offered the first pathophysiologic interpretation of
HRS. In 1932, Helvig and Schutz introduced the term “a
liver and kidney syndrome,” to describe a type of acute
renal impairment that occurred following biliary surgery [4].
The definition of HRS evolved with time, and the term
became synonymous with severe organ dysfunction that
involved both the liver and kidneys simultaneously. In 1956,
Hecker and Sherlock studied nine patients with advanced
liver disease and renal impairment characterised by oliguria,
hyponatraemia, low urinary sodium excretion, and absence
of proteinuria [5, 6]. All patients died in hospital and
postmortem findings showed normal renal histology. By
correlating these observations with other relevant findings
(i.e., low blood pressure, high cardiac output, and highly
oxygenised peripheral venous blood), the authors postulated
that peripheral arterial vasodilation was the key underlying
mechanism for the development of HRS [5, 6]. This theory
was strengthened by the observation that noradrenaline and
volume expansion performed in three patients led to a tran-
sient improvement in the renal function. In 1970, Epstein et
al. demonstrated the importance of splanchnic and systemic
vasodilation together with renal vasoconstriction as a foun-
dational concept in the pathophysiology of HRS [7]. In 1972,
Vesin described HRS as “functional renal insufficiency in
cirrhosis” and noted that the disease was often terminal [8].
Koppel et al. in 1969 and Iwatsuki et al. in 1973 provided com-
pelling evidence for the functional nature ofHRS [9, 10]. Kop-
pel et al. reported reversal of the renal dysfunction when kid-
neys belonging to six patients with advanced liver disease and
HRS were transplanted into recipients with end-stage kidney
disease and normal liver function [9]. Iwatsuki et al. reported
that liver transplantation in three cirrhotic patients with
HRS led to improved liver and renal function within two
weeks of operation [10]. Investigations by Schroeder et al.,
Arroyo et al., and Ring-Larsen et al. contributed to the under-
standing of the role of neurohormonal vasoconstrictor path-
ways (RAAS and SNS) in the genesis of HRS [11–13]. Building
on advances in the field, Schrier et al. proposed an updated
hypothesis for the pathophysiology of HRS, the peripheral
arterial vasodilation theory [14]. In 1978, a consensus con-
ference met in Sassari, Italy, to define diagnostic criteria
for HRS [15]. The Sassari criteria did not receive widespread
acceptance and were considered restrictive by many practic-
ing physicians [15]. Finally, 1996 marked a watershed, when
the International Ascites Club (IAC) produced diagnostic
criteria for HRS that were adopted internationally [15].These
were later revised in 2007 [16].
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4. Diagnostic Criteria and Their Limitations
Due to the lack of specific biochemical or radiologic markers,
the diagnosis of HRS is based on criteria for excluding other
causes of renal impairment that may be found in cirrhosis.
The criteria defined by the IAC are listed as follows.
Diagnostic Criteria forHRS (Reproducedwith Permission from
“John Wiley and Sons,” Arroyo et al. [15])
Major Criteria
(i) Chronic or acute liver disease with advanced hepatic
failure and portal hypertension.
(ii) Low GFR as indicated by serum creatinine >
1.5mg/dL or 24 hr creatinine clearance < 40mL/min.
(iii) Absence of shock, on-going bacterial infection, and
current or recent treatment with nephrotoxic drugs
and absence of gastrointestinal fluid losses (repeated
vomiting or intense diarrhoea) or renal fluid losses
(weight loss > 500 g/day for several days in patients
with ascites without peripheral oedema or 1000 g/day
in patients with peripheral oedema).
(iv) No sustained improvement in renal function
(decrease in serum creatinine ≤ 1.5mg/dL or increase
in creatinine clearance to ≥ 40mL/min) following
diuretic withdrawal and expansion of plasma volume
with 1.5 L of isotonic saline.
(v) Proteinuria < 500mg/dL and no sonographic evi-
dence of obstructive uropathy or parenchymal renal
disease.
Additional Criteria
(i) Urine volume < 500mL/day.
(ii) Urinary sodium < 10mEq/L.
(iii) Urinary osmolality greater than plasma osmolality.
(iv) Urine red blood cells < 50 per high power field.
(v) Serum sodium < 130mEq/L.
Revised Diagnostic Criteria for HRS (Reproduced with Permis-
sion from “BMJ Publishing Group Limited,” Salerno et al. [16])
(i) Cirrhosis with ascites.
(ii) Serum creatinine > 133 𝜇mol/L (1.5mg/dL).
(iii) No improvement in serum creatinine (decrease to a
level of ≤ 133 𝜇mol/L) after ≥ 2 days with diuretic
withdrawal and volume expansion with albumin; the
recommended dose of albumin is 1 g/kg of body
weight/day up to a maximum of 100 g/day.
(iv) Absence of shock.
(v) No current or recent treatment with nephrotoxic
drugs.
(vi) Absence of parenchymal kidney disease as indicated
by proteinuria> 500mg/day, microscopic haematuria
(>50 red blood cells per high power field), and/or
abnormal renal ultrasonography.
The revised criteria incorporate several new iterations which
include (i) removal of creatinine clearance, (ii) recognition
that on-going bacterial infection, in the absence of septic
shock, no longer excludes a diagnosis of HRS, (iii) preference
for the choice of albumin rather than saline for plasma
expansion, and (iv) removal of the minor diagnostic criteria
[16].
The IAC classifies HRS into type 1 and type 2. Type
1 HRS is a rapid progressive renal impairment defined by
doubling of the serum creatinine to a level > 2.5mg/dL or >
226𝜇mol/L in less than two weeks [16]. Type 2 HRS is
moderate renal impairment (serum creatinine > 1.5 and up to
2.5mg/dL or > 133 and up to 226𝜇mol/L) with a steady pro-
gressive course that evolves over weeks to months [16].
Acute deterioration in circulatory, renal, and hepatic function
is characteristic of type 1 HRS, while these abnormalities
develop more gradually in type 2 HRS. Type 1 HRS is often
associated with a precipitating factor, while type 2 HRS
typically develops de novo in patients with refractory ascites.
Rarely, type 2 HRSmay progress into type 1 HRS as a result of
a triggering event. Prognosis is poor ranging frommonths in
type 2 HRS to weeks in type 1 HRS.
The IAC diagnostic criteria have several shortcomings.
The serum creatinine should be interpreted with caution in
patients with cirrhosis [17–20]. These patients have lower
baseline serum creatinine than normal due to (i) reduced
endogenous creatinine production related to decreased hep-
atic synthesis and decreased muscle mass frommalnutrition,
(ii) medication related increased tubular secretion of creati-
nine, (iii) fluctuations in serum creatinine in patients with
cirrhosis and large volume ascites (e.g., following diuretic
therapy or paracentesis with volume expansion), and (iv)
laboratory based underestimations of serumcreatinine due to
interactions with bilirubin [17–20]. As such, creatinine based
measurements run the risk of overestimating renal function
and underestimating the severity of renal impairment, which
raises two important considerations. Firstly, a need exists to
developmore accurate laboratory and imaging biomarkers of
renal function. Cystatin C and NGAL (neutrophil gelatinase-
associated lipocalin) have been advocated as renal biomark-
ers but are expensive and not widely available. As yet, stan-
dard imaging tests have proven unreliable for detecting HRS
and differentiating it from other types of renal impairment.
Secondly, expert consultation and consensus are required to
determine if the serum creatinine threshold (>1.5mg/dL) for
HRS should be lowered to allow patients to be diagnosed and
treated while being at an earlier stage [21].
Current IAC criteria do not consider the clinical scenario
of HRS developing in patients with underlying chronic renal
disease.There is an increasing realisation that patients that fit
this category do exist but go unrecognized according to the
definitions of the existing criteria [21, 22]. Munoz proposes
that patients with HRS superimposed on chronic renal
disease be categorised as having type 3 HRS [22]. Finally, it
should be acknowledged that adherence to the IAC criteria
is not always possible. As HRS is a diagnosis of exclusion, the
diagnostic pathway can be complex at times, labour intensive,
and prone to error. Some patients that do not fulfil the full
IAC diagnostic criteria may be treated as having “presumed”
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HRS, based on the index of clinical suspicion. Three studies
highlight these challenges. Salerno et al., in a study involving
253 patients with cirrhosis and renal failure, found that the
diagnosis of HRS could only be “presumed” in 36% (𝑛 = 42)
as not all the IAC criteria could be met [23]. In 17% (𝑛 = 20),
diuretic therapy was tapered but not stopped and in 6% (𝑛 =
7) urinalysis could not be performed due to oligo-anuria
or showed red blood cells and/or proteins due to bladder
catheterisation or due to previous parenchymal renal disease,
while in 7% (𝑛 = 8) ultrasound showed preexisting renal
abnormalities [23]. Interestingly, the authors found no sig-
nificant differences in the clinical characteristics, clinical-
pathologic scores, or outcomes between presumed cases com-
pared with cases that met the full criteria [23]. Servin-Abad
et al. performed a retrospective analysis on 140 patients diag-
nosed with HRS from 1996 to 2004. The authors found that
only 41 patients (29.3%) met the IAC criteria [24]. Causes of
misdiagnosis included parenchymal renal disease (15.2%),
acute tubular necrosis (ATN) (35.4%), active sepsis (34.3%),
drug induced renal disease (4%), and others (11.1%) [24].Watt
et al. found that only 59% of patients with a clinical diagnosis
of HRS met IAC criteria [25].
5. Epidemiology
Incidence. In a study in 1993, prior to the introduction of
IAC criteria, Gines et al. reported that HRS had an incidence
of 18% at one year and 39% at five years in patients with
cirrhosis and ascites [26]. In a 2010 study utilising the revised
diagnostic criteria, Montoliu et al. evaluated the incidence
of functional renal impairment in 263 consecutive cirrhotic
patients with ascites [27]. The authors found that 49%
of patients developed functional renal impairment during
follow-up (mean follow-up of 41 months). The annual inci-
dence of HRS was 7.6% (𝑛 = 20) (type 1 = 7, type 2 = 13).
Prevalence. The prevalence of HRS (utilising the revised
diagnostic criteria) in patients with cirrhosis and ascites
ranged from 13 to 45.8%. Salerno et al. performed a prospec-
tive study of 253 consecutive patients with cirrhosis and
renal impairment admitted to 21 Italian hospitals [23]. The
prevalence ofHRSwas 45.8% (𝑛 = 116) (30% type 1 and 15.8%
type 2). A prospective study byMartin-Llahi et al. of 562 con-
secutive patients with cirrhosis and renal impairment admit-
ted to a single institution found HRS prevalence of 13% [28].
A prospective study by Thabut et al. of 100 consecutive
patients with cirrhosis and renal impairment admitted to five
French hospitals found HRS prevalence of 27% [29]. Retro-
spective studies suggest thatHRS is present in 17%of cirrhotic
patients admitted to hospital with ascites and in >50% of
patients dying from end-stage liver failure [30, 31].
Age. Most patients with HRS are in their sixth or seventh
decade. Salerno et al. reported the mean age as 62 ± 1.2 years
(type 1 HRS) and 68 ± 1.6 years (type 2 HRS) [23], while
Martin-Llahi et al. reported a mean age of 60 ± 12 years [28].
A pooled analysis by Garcia-Tsao et al. in 509 HRS patients
from 14 studies found a mean age of 54 years [1].
Gender. There is a male preponderance, which is reflective of
the gender balance of the underlying cirrhosis. Salerno et al.
reported that 76.3% of type 1 HRS and 70% of type 2 HRS
patientsweremales [23], similar toMartin-Llahi et al. (76.7%)
[28] and Garcia-Tsao et al. [1].
Aetiology of Cirrhosis. Salerno et al. identified the aetiology
of cirrhosis as alcohol (type 1 HRS 46.1%; type 2 HRS 55%),
viral (type 1 HRS 31.6%; type 2 HRS 40%), alcohol + viral
(type 1 HRS 10.5%; type 2 HRS 2.5%), and others (type 1 HRS
11.8%; type 2 HRS 2.5%) [23]. According to the pooled anal-
ysis by Garcia-Tsao et al., alcohol-related cirrhosis was the
underlying aetiology in 57% (40 to 78%, interquartile range,
IQR) [1].
6. Precipitating Factors
HRS develops on the background of advanced liver disease,
as highlighted by the high mean Child-Pugh (CP) score of
11.2 (11-12; IQR) [1]. Cirrhosis is themost commonunderlying
liver disease but other aetiologies include fulminant hepatic
failure and severe acute alcohol-related hepatitis [32]. The
frequency of HRS in fulminant hepatic failure and severe
acute alcohol-related hepatitis has been reported to be as high
as 55% and 30%, respectively [22, 33, 34]. HRS may occur
spontaneously (typically in type 2 HRS) or may be triggered
by a precipitating factor (in >70% of cases of type 1 HRS) [35].
The most common precipitating factor is spontaneous
bacterial peritonitis (SBP). SBP refers to infection of ascitic
fluid (typically by enteric Gram-negative bacteria) in the
absence of a specific intra-abdominal source for the sepsis.
SBP has a close chronologic and pathologic connection with
HRS where it typically precedes its onset. Follo et al. [36]
found that SBP precipitated HRS in 28% of cases despite
appropriate treatment and resolution of infection. Renal
impairment was transient in 21 cases (32%), stable in 26 cases
(40%), and progressive in 18 cases (28%). SBP may trigger
HRS via two postulated mechanisms [35, 37]: (i) release
of proinflammatory cytokines (interleukin-6 and tumour
necrosis factor) and endotoxins leading to increased produc-
tion of nitric oxide and other vasodilator substances and (ii)
sepsis-induced cardiomyopathy leading to decreased cardiac
output.
The second most common precipitating factor for HRS is
large volume paracentesis (LVP) without plasma expansion.
LVP exacerbates the hyperdynamic circulation in cirrhosis,
which leads to progressive systemic vasodilation and arterial
underfilling. Gines et al. found that LVP (4–6 L/day), per-
formed without intravenous albumin replacement, precipi-
tated HRS in 21% of 53 cases [38]. In contrast, there were
no cases of HRS when LVP was performed with intravenous
albumin replacement. Ca´rdenas et al. found that renal impair-
ment occurred in 11% of 175 of cirrhotic patients that
experienced gastrointestinal bleeding [39]. In these patients,
the aetiology was ATN not HRS. Gastrointestinal bleeding
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may induce a systemic inflammatory response associated
with activation of proinflammatory cytokines that stimulate
nitric oxide and other vasodilator substances. Furthermore,
gastrointestinal bleeding increases susceptibility to infection,
a vicious cycle that may generate further cytokines release,
and rebleeding. Certain medications such as nonsteroidal
anti-inflammatory drugs (NSAIDs) can precipitate HRS in
those with borderline renal function. Renal vasoconstriction
is initially counterbalanced by increased renal production of
vasodilating prostaglandins (e.g., renal prostaglandin E2 and
prostacyclin). NSAIDs can inhibit renal prostaglandin syn-
thesis and thus aggravate renal vasoconstriction. Intravascu-
lar volume depletion by injudicious diuretic use has also been
considered as a potential trigger for HRS; however, evidence
to support this is lacking [32]. Biliary obstruction may
precipitate HRS due to the action of bile acids and oxidative
stress from free radical-induced tissue damage. Bile acids can
alter the renal handling of electrolytes and water by blocking
the sodium-hydrogen antiport protein [40]. Oxidative stress
promotes the formation of a variety of vasoconstrictor sub-
stances including endothelin-1, cysteinyl leukotrienes, and
F2-isoprostanes [40].
7. Predictors of HRS
Several studies have been performed to investigate potential
predictors for HRS. Gines et al., in a study of 234 patients,
identified 16 variables that may be useful as predictors of
HRS on univariate analysis [26]. The variables included
hepatomegaly, oesophageal varices, history of ascites, nutri-
tional status, GFR, blood urea nitrogen, serum sodium and
potassium, plasma renin activity, plasma noradrenaline,
serum and urinary osmolality, urinary sodium excretion, free
water clearance after a water load, and mean arterial pressure
(MAP). However, only three independent variables, absence
of hepatomegaly, high plasma renin activity, and low serum
sodium, were found to be predictive of HRS on multivariate
analysis. Montoliu et al., in a study of 263 patients, found
that older age, high baseline serum creatinine, and a high CP
score were independent predictors for HRS on multivariate
analysis [27]. These variables may reflect the longer duration
of the liver disease and the greater severity of the liver and
renal impairment. Platt et al., in a study of 180 patients with
nonazotemic liver disease, reported that the resistive index
(RI) of the intrarenal arteries on Doppler ultrasound pre-
dicted the development of renal dysfunction, including HRS
[41]. Renal dysfunction developed in 55% of patients with an
elevated RI at baseline (≥0.7), including 6% of patients with
a normal RI. HRS developed in 26% of patients with elevated
baseline RI and 1% of patients with normal baseline RI.
Patients that went on to develop HRS had higher baseline RIs
(0.77) than patients that developed non-HRS renal impair-
ment (0.72, 𝑃 < 0.05) or patients with preserved normal
renal function (0.65, 𝑃 < 0.01). The RI may be regarded
as a barometer of the intrarenal vascular tone and this
is elevated in HRS due to increased vasoconstrictor activity.
8. Clinical and Laboratory Findings
HRS does not have specific clinical findings. Its physical
manifestations broadly reflect the underlying advanced liver
disease, renal impairment, and circulatory abnormalities
present. Clinical findings of advanced liver disease include
hepatomegaly, ascites, stigmata of portal hypertension (e.g.,
gastroesophageal varices, caput medusa, hepatic encephalop-
athy, etc.), jaundice, pruritus, coagulopathy, gynaecomastia,
finger clubbing, palmar erythema, spider naevi, and con-
stitutional disturbances such as weakness, fatigue, anorexia,
and poor nutritional status. Patients with type 1 HRS are
more severely affected than patients with type 2 HRS.
Acute oliguria is typically present in type 1 HRS, while the
urine output shows a more gradual decline in type 2 HRS.
Circulatory disturbances include a hyperdynamic circulation
and reduced systemic vascular resistance. This may manifest
clinically as lowMAP, low jugular venous pressure, tachycar-
dia, a bounding pulse, and wide pulse pressure.The following
laboratory findings are suggestive of HRS [26]: elevated
plasma renin activity, elevated plasma noradrenaline activity,
hyponatraemia, hyperkalaemia, elevated blood urea nitro-
gen, decreased plasma osmolality, elevated urinary osmolal-
ity, and decreased urinary sodium excretion. Serum abnor-
malities that reflect the severity of the liver disease include
hyperbilirubinemia, hypoalbuminemia, and prolonged pro-
thrombin time.
9. Prognosis
HRS is one of the most lethal complications of cirrhosis
(Figure 2). Prognosis is invariably poor ranging frommonths
in type 2 HRS to weeks to months in type 1 HRS [42, 43].
Studies have been performed to define clinical parameters
that track survival in HRS. In 2005, Alessandria et al. studied
105 patients with cirrhosis and HRS (39% type 1 and 61% type
2) [42] and found that HRS type and MELD (model for end-
stage liver disease) score were variables that associated inde-
pendently with survival onmultivariate analysis. MELD is an
internationally recognised scoring system developed for
patients with advanced liver disease that is a predictor of
three-month mortality and determines priority listing for
liver transplantation [42, 44]. It is calculated according to the
following formula: 9.6 ×loge (creatinine mg/dL) + 3.8 ×loge
(bilirubin mg/dL) + 11.2 ×loge (international normalised
ratio, INR) + 6.4 [42]. Patients with type 1 HRS had a MELD
score ≥ 20 and a median survival of one month [42]. For type
2 HRS, the median survival was 11 months for a MELD score
< 20 and threemonths for aMELD score≥ 20 [42]. Schepke et
al. reported similar findings in a 2006 study that involved 88
patients with cirrhosis and renal failure [43], some with HRS
(17–39.8% type 1, 22.7% type 2), and non-HRS renal impair-
ment. On multivariate analysis, the authors found that type 1
HRS and the MELD score were independent variables asso-
ciated with survival. The mean MELD score was higher in
patients with HRS than in patients with non-HRS renal
impairment (23.8 versus 18.3, 𝑃 = 0.002) [43]. The estimated
survival time was 3.4 months for type 1 HRS, 10.9 months for
type 2 HRS, and 16.1 months for non-HRS renal impairment
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Figure 2: Probability of survival in cirrhotic patients with different types of renal impairment: nonazotemic patients (bold continuous line),
type 2 HRS (dotted line), and type 1 HRS (continuous line) (reproduced with permission from “BMJ Publishing Group Limited,” Salerno
et al. [16]).
[43]. In 2010, Yang et al. performed a longitudinal assessment
of prognostic factors in 103 patients with HRS (65% type 1
and 35% type 2) [45] and revealed that temporal changes (Δ)
in four clinical parameters were associated with survival
on time dependent multivariate analysis. These parameters
includedΔMELD score simple, Δ serum creatinine,Δ serum
bilirubin, and Δ serum albumin [45]. ΔMELD score simple
was calculated according to the following formula: [3.8 ×
log bilirubin (mg/dL)] + 9.6 × log [creatinine (mg/dL) +
6.43] [45]. The authors found that ΔMELD score simple was
superior to baseline and changes inMELD score in predicting
prognosis.The authors also found that increasing serum crea-
tinine and bilirubin affected survival adversely, while increas-
ing serum albumin had a beneficial effect. In a 2012 study
involving 68 patients with type 1 HRS, Martinez et al.
reported that the aetiology of the liver disease, the serum
creatinine at the time of initiation of treatment, and the
urinary sodiumwere useful prognostic factors [46].The aeti-
ologies of the liver disease included (in decreasing order of
survival) autoimmune hepatitis, cardiac, idiopathic, viral,
viral + alcohol, alcohol, and neoplasia.The authors also found
that higher serum creatinine on admission and a urinary
sodium < 5mEq/L were associated negatively with survival.
10. Treatment Options
Vasoconstrictor Therapy. This is the primary medical treat-
ment for type 1 HRS. These drugs function by causing vaso-
constriction of the grossly dilated splanchnic vascular bed
resulting in increased systemic vascular return and increased
MAP, which in turn suppresses the RAAS and SNS and
improves renal perfusion. Albumin augments the potency of
vasoconstrictor drugs by improving cardiac function and
increasing the effective arterial blood volume. The Acute
Dialysis Quality Initiative (ADQI) work group recommends
the use of vasoconstrictor drugs combined with plasma
expansion with albumin, as first line treatment for type 1
HRS [47]. Terlipressin is the vasoconstrictor drug of choice
in Europe. It is a vasopressin analogue that acts on the V1
vasopressin receptors in vascular smooth muscle cells. The
results of randomised controlled trials and meta-analysis
suggest that the combination of terlipressin and albumin is
effective in improving renal function in 40 to 50% of patients
with type 1 HRS [48–50]. Patients with type 2 HRS may
also benefit. Response to treatment is characterised by a
decrease in the serum creatinine and an increase in the urine
volume, serum sodium, and MAP. Median response time
to treatment is 14 days [48]. Predictors of response include
pretreatment bilirubin < 10mg/dL and an increase of MAP ≥
5mmHg at day three of therapy [50–52]. Following with-
drawal of treatment, HRS recurs in 20%, although retreat-
ment is generally effective [16]. Terlipressin may cause organ
and peripheral ischaemia and is contraindicated in patients
with cardiovascular disease, cerebrovascular disease, and
peripheral vascular disease. Significant complications are
reported in 10 to 12% [16, 48–50]. It is unlikely that vaso-
constrictor drugs improve survival beyond the short term.
A multicentre randomised controlled trial comparing terli-
pressin and albumin to albumin alone in 46 patients with
HRS showed improved renal function in the former group
(43.5% versus 8.7%, 𝑃 = 0.017), but no survival advantage in
either group at three months (27% versus 19%, 𝑃 = 0.7) [53].
A second multicentre randomised controlled trial in 56
patients with HRS comparing terlipressin to placebo and
albumin found similar survival for both groups at 180 days
(42.9% versus 37.5%, 𝑃 = 0.8) [54]. Other vasoconstrictor
drugs used in HRS include noradrenaline, midodrine, and
octreotide. These have lower costs than terlipressin and,
unlike terlipressin, are licensed for clinical use in North
America. Noradrenaline and midodrine are 𝛼-adrenergic
agonists, which act on the 𝛼
1
-adrenergic receptors in vascular
smooth muscle cells. Octreotide is a long acting somatostatin
analogue that inhibits glucagon and other vasodilator pep-
tides. Only limited information is available about the efficacy
of these alternative drugs.
Transjugular Intrahepatic Portosystemic Shunt (TIPS). TIPS
involves the insertion of an intrahepatic stent that connects
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the portal vein to the hepatic vein. This shunts portal
blood into the systemic circulation, which reduces the portal
pressure and increases the systemic venous return. In turn,
this treats the arterial underfilling and the overactivity of the
RAAS and SNS. Unfortunately, most patients with HRS are
ineligible for TIPS due to contraindications (e.g., INR > 2,
serum bilirubin > 5mg/dL, CP score > 11, and cardiopul-
monary disease). Furthermore, TIPS can aggravate the liver
failure and precipitate encephalopathy.
Brensing et al. assessed the outcome following TIPS in 41
nontransplantHRSpatients [55]. 31 patients receivedTIPS (14
patients, type 1, and 17 patients, type 2), and tenwere excluded
due to advanced liver disease. Renal function showed a
gradual nonnormalized improvement within two weeks after
TIPS. Overall survival following TIPS was 81% at three
months, 71% at six months, 48% at 12 months, and 35% at 18
months. In contrast, seven of the ten non-TIPS patients died
within three months. The authors concluded that TIPS could
provide a survival benefit in well-selected HRS patients.
Testino et al. performed TIPS in 18 type 2 HRS patients with
refractory ascites that were awaiting liver transplantation
[56]. The study found that TIPS improved the renal function
and led to complete resolution of ascites in eight patients and
partial resolution in ten patients. The authors suggested that
TIPS may be used as a bridge to transplantation by preparing
patients for surgery with improved renal function. Guevara
et al. assessed the effects of TIPS on renal function and the
vasoactive systems [57] and found improved renal function to
nonnormalized levels in six of seven patients with type 1HRS.
The serum creatinine fell from 5 ± 0.8 to 1.8± 0.4mg/dL by 30
days. Reduced activity of the RAAS and SNS was reflected by
a reduction in serum renin, aldosterone, and norepinephrine
levels. Testino et al. performed TIPS in nine patients with
type 1 HRS and acute alcohol-related hepatitis [58], which
resulted in a nonnormalized improvement in renal func-
tion (decreased serum creatinine and blood urea nitrogen
and increased urine volumes). The serum creatinine fell
from5.2± 0.9mg/dL to 1.6± 0.6mg/dL by 30 days.Wong et al.
evaluated the combination of medical therapy (midodrine,
octreotide, and albumin) and TIPS in type 1 HRS [59];
serum creatinine decreased to < 135 𝜇mol/L for at least three
days following medical therapy in ten patients. Half of the
responders underwent TIPS and showed resolution of ascites
with normalisation of renal function (GFR 96 ± 20mL/min)
and serum renin and aldosterone by 12 months.
The ADQI work group recommends that (i) TIPS should
not be used as the first line treatment for type 1 HRS due to
insufficient data and (ii) TIPS may be used in patients with
type 2 HRS and refractory ascites [47].
Extracorporeal Support Systems. Renal replacement therapy
(RRT) may be used to treat specific complications of renal
impairment such as metabolic acidosis, hyperkalaemia, vol-
ume overload, and uraemic symptoms. It may have a role
in patients who are unresponsive to vasoconstrictor drugs
and where TIPS is contraindicated. In some circumstances,
it may provide a bridge to liver transplantation. Side effects
include hypotension, coagulopathy, and infection. Continu-
ous venovenous haemofiltration is preferred to intermittent
haemodialysis in unstable patients and those at risk of
developing raised intracranial pressure. The ADQI work
group recommends that RRT should be avoided in type 1HRS
patients unless there is an acute reversible component or an
intention to pursue transplantation [47].
Molecular adsorbent recirculating system (MARS) is a
modified dialysis technique for extracting albumin bound
and water-soluble substances from the blood. This removes
vasodilator substances such as nitric oxide, tumour necrosis
factor, and cytokines, which are implicated in the pathogene-
sis of HRS. Mitzner et al. performed a randomised controlled
study in type 1 HRS patients undergoing either MARS (eight
patients) or standard treatment (five patients) [60] and found
a significant reduction in the serum creatinine and bilirubin
and a significant increase in the serum sodiumandprothrom-
bin activity. The MARS group showed improved short-term
survival comparedwith the control group (survival was 37.5%
at seven days and 25% at 30 days forMARS versus 0% at seven
days for the control group). In a separate study involving
eight subjects, Mitzner et al. found that MARS improved
multiorgan function in type 1 HRS patients [61]. Wong et al.
performed a study involving six type 1 HRS patients with
refractory ascites that had failed vasoconstrictor treatment
[62] and found thatMARSwas not associatedwith significant
improvements in theGFR, neurohormonal levels, or systemic
haemodynamics. In a study of 32 patients, Lavayssie`re et al.
found that only 28% of type 1 HRS patients showed complete
renal recovery after 28 days [63]. More recently, a large
randomised controlled trial (RELIEF) involving 19 European
centres comparing MARS with standard therapy in patients
with acute-on-chronic liver failure [64] reported that while
MARS provided temporary organ benefit (liver, kidney, and
brain), it did not improve overall survival.
Prometheus is an extracorporeal technique involving
fractional plasma separation and adsorptionwith haemodial-
ysis for removing water-soluble and albumin bound sub-
stances. Rifai et al. found that Prometheus treatment in ten
HRS patients led to improved serum creatinine, urea, biliru-
bin, bile acids, and ammonia concentrations [65]. Given the
lack of a definitive survival benefit and high costs, the ADQI
work group suggests that extracorporeal support systems
should be limited to research protocols.
Liver Transplantation. Liver transplantation is the definitive
treatment for HRS [66–72]. The five-year survival for HRS is
60% for patients that underwent liver transplantation com-
pared with 0% for patients that did not undergo liver trans-
plantation [66]. The use of the MELD scoring system, which
allocates liver grafts according to the “sickest first” policy, has
increased the proportion of HRS patients that have received
a liver transplant. In addition to orthotopic liver transplan-
tation (OLT) [40], some centres have also performed living
donor liver transplantation (LDLT). Advantages of LDLT
include increasing the donor pool, the possibility of planned
surgery, shorter ischaemic duration, and younger donor age
[73]. A potential pitfall is that the smaller graft may be insuf-
ficient to sustain hepatic function [68]. A report by Lee et al.
involving 71 HRS patients (48OLT and 23 LDLT) found com-
parable outcomes for both techniques [73]. The three-year
survival was 85.3% for LDLT compared with 60.9% for OLT.
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Patients with HRS have worse posttransplant outcomes
than patients without HRS. This includes reduced short- and
long-term survival, increased risk of bleeding and infection,
and longer hospital stay [66, 67]. The five-year survival com-
paring patients with HRS that have received a liver transplant
to patients without HRS that have received a liver transplant
is 60% versus 68% (𝑃 < 0.03) [66, 67]. The pretransplant
renal function is a major predictor of outcomes following
transplantation, with less favourable outcomes for patients
with pretransplant renal dysfunction [66, 72]. Restuccia et al.
suggested that reversal of the renal dysfunction prior to trans-
plantation improves posttransplant outcomes [68].The study
found that HRS patients treated with vasopressin analogues
before transplantation had similar outcomes to controls with
normal renal function [68]. Both groups had comparable
survival (three-year survival 100% in HRS-treated group
versus 83% in controls,𝑃 = 0.15), frequency of posttransplant
renal dysfunction, and length of hospital stay.
Between 58 and 94% of patients with HRS demonstrate
recovery of renal function after liver transplantation [74–76].
Factors associated with a failure of renal recovery include the
time interval between onset of HRS and transplantation (≥
4–6 weeks), dialysis for ≥ 8 weeks, and a serum creatinine
of ≥ 2mg/dL [74–77]. Such patients may benefit from simul-
taneous liver and kidney transplantation. The ADQI work
group recommends that liver transplantation alone should be
performed if the duration of type 1 HRS is < 4 weeks, while
simultaneous liver and kidney transplantation should be
performed if there is a risk that renal recovery will not occur
[47].
11. Prophylaxis
Prophylactic treatment may be beneficial in reducing the risk
of developing HRS. Sort et al. performed a randomised con-
trolled trial in cirrhotic patients with SBP [78]. 126 patients
were randomised to one of two treatment arms, albumin plus
cefotaxime (antibiotic) or cefotaxime alone. The study found
that patients that received albumin plus cefotaxime had a
lower incidence of developing renal impairment than patients
that received cefotaxime alone (10% versus 33%, 𝑃 < 0.01).
In-hospital and three-month mortality rates were signifi-
cantly lower in the albumin plus cefotaxime group compared
with the cefotaxime group (10% versus 29%, 𝑃 = 0.01,
and 22% versus 41%, 𝑃 = 0.03). Pentoxifylline is a phospho-
diesterase inhibitor with beneficial effects on renal function.
Tyagi et al. performed a randomised controlled trial involving
70 patients with cirrhosis, ascites, and a baseline normal renal
function [79]. Patients were randomised into two treatment
arms, pentoxifylline or placebo. Baseline, one-month, three-
month and sixth-month laboratory and clinical parameters
were assessed. HRS developed in two patients in the pen-
toxifylline group (2.9%) compared with ten patients in the
placebo group (14.3%). The six-month mortality was one in
two HRS patients in the pentoxifylline group compared with
three in ten HRS patients in the placebo group.
12. Conclusion
Over the last century, much has been learnt about the patho-
physiology, clinical behaviour, and natural history of HRS.
Standardised diagnostic criteria have been developed and
implemented worldwide, allowing for more uniform diag-
nosis and consistent reporting of the disease. Limitations in
the diagnostic criteria exist, but as yet, no reliable diagnostic
marker exists for HRS. Future directions should include the
development of an accurate diagnostic test for HRS. This is
important as an earlier diagnosis and thus treatment is likely
to improve survival. Several treatment options exist, but, at
present, only liver transplantation offers a genuine hope for
cure and longevity.
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